Literature DB >> 9693317

Mucosal immunodeficiency in HIV/SIV infection.

M Zeitz1, R Ullrich, T Schneider, S Kewenig, E Riecken.   

Abstract

The gastrointestinal tract is one of the major target organs for secondary infections and malignancies in HIV infection in humans indicating disturbed local immunologic defense mechanisms. Immunohistology and flow cytometric studies have demonstrated a more pronounced loss of CD4+ T cells in the intestinal mucosa compared to the peripheral blood in humans infected with HIV. In parallel, activated CD8+ T cells in the lamina propria are increased in this compartment. In SIV-infected nonhuman primates a very early loss of CD4+ T cells in the intestinal mucosa compared to the peripheral blood occurs already at 2 weeks after infection. Depletion and functional impairment of mucosal CD4+ T lymphocytes with consecutive altered cytokine secretion in HIV/SIV infection may explain the breakdown of the mucosal immune barrier leading to secondary opportunistic or nonopportunistic infections and secondary malignancies. In addition, due to the interrelation between the mucosal immune system and epithelium, these changes might be responsible for the partial small intestinal mucosal atrophy and maturational defects in enterocytes observed in HIV-infected patients.

Entities:  

Mesh:

Year:  1998        PMID: 9693317     DOI: 10.1159/000028013

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  6 in total

1.  HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Authors:  Aude G Chapuis; Corey Casper; Steve Kuntz; Jia Zhu; Annelie Tjernlund; Kurt Diem; Cameron J Turtle; Melinda L Cigal; Roxanne Velez; Stanley Riddell; Lawrence Corey; Philip D Greenberg
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Detection of immunoglobulin G antibodies to Neospora caninum in humans: high seropositivity rates in patients who are infected by human immunodeficiency virus or have neurological disorders.

Authors:  Janaína Lobato; Deise A O Silva; Tiago W P Mineo; Jodi D H F Amaral; Gesmar R Silva Segundo; Julia M Costa-Cruz; Marcelo S Ferreira; Aércio S Borges; José R Mineo
Journal:  Clin Vaccine Immunol       Date:  2006-01

3.  Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.

Authors:  Michael D George; Elizabeth Reay; Sumathi Sankaran; Satya Dandekar
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10.

Authors:  Paul Ashwood; Andrew Anthony; Franco Torrente; Andrew J Wakefield
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

5.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults.

Authors:  Steven A Yukl; Amandeep K Shergill; Valerie Girling; Qingsheng Li; Maudi Killian; Lorrie Epling; Peilin Li; Philipp Kaiser; Ashley Haase; Diane V Havlir; Kenneth McQuaid; Elizabeth Sinclair; Joseph K Wong
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.